Stallion Uranium Intersects Elevated Radioactivity and Alteration at Coyote; Continues Expanded Drill Program, Mobilizes Geophysical Survey

Stallion Uranium advanced drilling at its Moonlite Project’s Coyote target, completing ~3,527m of an expanded 5,500m Phase 1 program after early hits led to expansion from 4,000m. In the first three main-target holes, uranium-system indicators were consistent—elevated radioactivity (>300 cps) in all three, plus hydrothermal alteration and strong structural features including a graphitic fault zone—supporting the company’s geophysical model. The firm also mobilized an expanded high-resolution SWML-TDEM survey (three ~3.2 km lines) to better delineate conductive uranium-related features, with next milestones including remaining drilling completion and assay results from core.

Analysis

The market should treat this as a probability update, not a valuation event. In uranium explorers, gamma hits and alteration are only useful if they convert into assay grade, thickness, and continuity; until then the stock is trading on implied discovery odds, not asset value. That means the best-rewarded holder is usually the JV partner with broader land optionality and less single-hole binary risk, here SASKF, while STLNF gets the sharper upside/downside because it is the more direct expression of the drill thesis.

The second-order effect is district sentiment: if assays confirm mineralization, capital tends to rotate into the entire Athabasca basket, especially other early-stage names with nearby conductivity/structural targets and service providers tied to the basin drill season. If assays miss, the reversal is usually violent because small-cap uranium explorers have thin liquidity and financing overhangs; the expanded program itself also raises the odds of future dilution if follow-up drilling is required. The board change is probably noise, but in a microcap it can matter if paired with weak lab results or any pause in drilling cadence.

Consensus risk is over-weighting the phrase "radioactivity" and under-weighting the gap between anomalous field readings and economic uranium. The contrarian view is that this may be an underappreciated optionality setup for SASKF rather than a clean discovery in STLNF: the partner can benefit from any basin-wide validation with less binary exposure. The key falsifier over the next 1-3 months is assay data that fails to show coherent grade-width continuity, or TDEM results that do not sharpen a conductive target for the next hole.

Key Decisions for Investors

• Tactically long STLNF only into the assay window, sized small and with a hard stop if lab results fail to confirm the gamma signal; best case is a 2-3x move on discovery confirmation, but downside is a fast retrace on disappointment.
• Prefer SASKF as the lower-beta way to express Athabasca optionality over the next 1-3 months; if the program validates, SASKF can re-rate with less single-asset risk than STLNF.
• Do not chase after an initial headline pop; wait for the SWML-TDEM and assay sequence. If the stock gaps 15-20% on no assay, fade part of the move because the market is likely front-running unverified geology.
• Watch the uranium equities basket (URA/URNM) for sympathy flows; if sector momentum is already hot, the probability of a near-term overshoot in STLNF rises, but that should be treated as a trading event, not conviction.